Background Available evidence suggests that low-and middle-income countries (LMICs)
bear the greatest burden of severe neonatal hyperbilirubinemia characterized by …

The diagnosis and treatment of Plasmodium vivax malaria differs from that of Plasmodium
falciparum malaria in fundamentally important ways. This article reviews the guiding …

Background The reduction of tetrazolium salts by NAD (P) H to formazan product has been
widely used to determine the metabolic activity of cells, and as an indicator of cell viability …

Malaria elimination will be possible only with serious attempts to address asymptomatic
infection and chronic infection by both Plasmodium falciparum and Plasmodium vivax …

A barrier to eliminating Plasmodium vivax malaria is inadequate treatment of infected
patients. 8-Aminoquinoline–based drugs clear the parasite; however, people with glucose-6 …

Abstract Glucose‐6‐phosphate dehydrogenase (G6 PD) deficiency is an established
worldwide risk factor for severe hyperbilirubinaemia. This literature review examined the …

Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of
severe haemolysis following the administration of 8-aminoquinoline compounds …

The only currently available drug that effectively removes malaria hypnozoites from the
human host is primaquine. The use of 8-aminoquinolines is hampered by haemolytic side …

Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common
red blood cell enzyme deficiency worldwide. The disease is widely distributed in regions …

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked enzymopathy
caused by mutations in the G6PD gene. A medical concern associated with G6PD deficiency …